Preclinical
Biogen reported that its gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma.
Merck announced positive results from the late-stage KEYNOTE-522 study that should support its previous attempt that was stymied by a regulatory advisory committee in February and rejected by the U.S. FDA in March.
Nearly 50 infants with “bubble baby” disease developed a working immune system after they received a gene therapy that contained the AIDS virus, according to a new study.
Two new venture capital funds, Droia Ventures and Perceptive Advisors closed on new funds to invest in early-stage life science companies.
The Series A rounds are the latest in a string of financing announcements made over the past few months.
Eli Lilly announced a drug development collaboration with MiNA Therapeutics Limited focusing on five novel drug candidates that could be worth up to $245 million.
Clearance of the IND allows Samus to proceed with a Phase Ib trial to assess the safety, tolerability and pharmacokinetics of PU-AD in a small group of patients with recurrent malignant glioma.
The 24th Annual meeting of the American Society of Gene & Cell Therapy presents cutting-edge work in the booming area of gene and cell therapy. Here’s a look at a few of the highlights.
Shanghai-based Alebund Pharmaceuticals has raised $60 million in a new Series B financing round that will be harnessed to further drive the company’s focus on renal disease.
PRESS RELEASES